Make 50% From Billionaire Carl Icahn's Latest Target (GENZ)

Carl Icahn is ready for a brawl...

Back in October, we told you how a rogue virus had infected the manufacturing facilities of Genzyme, the biotech bellwether. The FDA ordered Genzyme to shut down its plant and cease producing Cerezyme and Fabrazyme, two of the company's most lucrative drugs. Revenue and earnings plunged.

Besides crippling sales and destroying physician and patient confidence, the snafu created worldwide shortages of the drugs. The shortage gave an opening to competing products from Shire and Protalix to enter Cerezyme's lucrative $1 billion-plus market.

Genzyme (NASDAQ: GENZ) shares have dropped 35% from their 2008 peak. It's trading at levels last seen more than five years ago. But if you bought on our advice in Growth Stock Wire and grabbed Genzyme when it dipped below $48 per share, you're up about 16%. And I think there's plenty more upside.

You see, despite the short-term execution problems, Genzyme is not hopeless. The company's core biologic drugs enjoy tremendous pricing power, lengthy patent protection, and little competition. Its impressive pipeline features a breakthrough drug for multiple sclerosis, a pill version of Cerezyme (it's an IV drug now), and a novel treatment to lower cholesterol.

Read the full story at Stockhouse